- Home
- HUT vs JANX Comparison
HUT vs JANX Comparison
Compare HUT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUT
- JANX
- Stock Information
- Founded
- HUT 2011
- JANX 2017
- Country
- HUT United States
- JANX United States
- Employees
- HUT N/A
- JANX N/A
- Industry
- HUT Finance: Consumer Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- HUT Finance
- JANX Health Care
- Exchange
- HUT Nasdaq
- JANX Nasdaq
- Market Cap
- HUT 1.6B
- JANX 1.6B
- IPO Year
- HUT N/A
- JANX 2021
- Fundamental
- Price
- HUT $16.70
- JANX $23.60
- Analyst Decision
- HUT Strong Buy
- JANX Strong Buy
- Analyst Count
- HUT 14
- JANX 7
- Target Price
- HUT $26.64
- JANX $94.29
- AVG Volume (30 Days)
- HUT 6.3M
- JANX 808.2K
- Earning Date
- HUT 08-12-2025
- JANX 08-06-2025
- Dividend Yield
- HUT N/A
- JANX N/A
- EPS Growth
- HUT N/A
- JANX N/A
- EPS
- HUT N/A
- JANX N/A
- Revenue
- HUT $132,459,000.00
- JANX $9,336,000.00
- Revenue This Year
- HUT $74.79
- JANX N/A
- Revenue Next Year
- HUT $116.78
- JANX $1,470.82
- P/E Ratio
- HUT N/A
- JANX N/A
- Revenue Growth
- HUT 0.24
- JANX 28.12
- 52 Week Low
- HUT $8.73
- JANX $22.48
- 52 Week High
- HUT $31.95
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- HUT 50.50
- JANX 41.60
- Support Level
- HUT $17.35
- JANX $24.45
- Resistance Level
- HUT $18.60
- JANX $27.28
- Average True Range (ATR)
- HUT 1.07
- JANX 1.35
- MACD
- HUT -0.19
- JANX -0.09
- Stochastic Oscillator
- HUT 39.39
- JANX 22.20
About HUT Hut 8 Corp.
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.